IDEAYA Biosciences, Inc.
IDEAYA Biosciences, Inc. (IDYA): 23 pipeline candidates · 3 upcoming catalysts · ~26 mo cash runway · 13 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
26.1 months
D/E 0.10 · 1% dilution
Lead: Phase 2/Phase 3
23 candidates
3 upcoming, next in ~181d
1 buy · 0 sells (180d)
A transparent, data-derived signal for IDEAYA Biosciences, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$3.0B
Cash
$158.8M
Quarterly Burn
$75.2M
Runway
26.1 mo
Revenue
$6.6M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (23 candidates)
| Drug | Phase |
|---|---|
| Binimetinib | Phase 1/Phase 2 |
| Crizotinib | Phase 2/Phase 3 |
| Dacarbazine | Phase 2/Phase 3 |
| Darovasertib | Phase 2 |
| delpacibart zotadirsen | — |
| fenfluramine | Phase 3 |
| GSK4418959 | Phase 1 |
| IDE-161 | Phase 1 |
| IDE034 | Phase 1 |
| IDE161 | Phase 1 |
Showing 10 of 23 candidates. Sign up for full pipeline.
Upcoming Catalysts (3)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
254
Total value held
$3.27B
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 14,530,506 | $484.0M |
| fmr llc | 13,172,103 | $438.9M |
| blackrock, inc. | 8,442,133 | $281.3M |
| vanguard capital management llc | 7,464,844 | $248.7M |
| baker bros. advisors lp | 3,946,515 | $131.5M |
| state street corp | 3,781,167 | $126.0M |
| federated hermes, inc. | 2,987,107 | $99.5M |
| adage capital partners gp, l.l.c. | 2,823,500 | $94.1M |
| fiera capital corp | 2,527,076 | $84.2M |
| geode capital management, llc | 2,500,724 | $83.3M |
Showing top 10 of 254 institutional holders of IDEAYA Biosciences, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in IDEAYA Biosciences, Inc.'s pipeline?
IDEAYA Biosciences, Inc. (IDYA) has 23 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is IDEAYA Biosciences, Inc.'s lead drug candidate?
IDEAYA Biosciences, Inc.'s most advanced tracked candidate is Binimetinib (Phase 1/Phase 2) for Metastatic Uveal Melanoma.
What is IDEAYA Biosciences, Inc.'s next catalyst?
IDEAYA Biosciences, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Open-Label, Single-Arm, Phase 3 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenf" — expected December 16, 2026.
What is IDEAYA Biosciences, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, IDEAYA Biosciences, Inc. has approximately 26.1 months of cash runway.
What is IDEAYA Biosciences, Inc.'s market capitalization?
IDEAYA Biosciences, Inc.'s market capitalization is approximately $3.0B.
Get the full picture on IDEAYA Biosciences, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.